Literature DB >> 24088848

Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis.

Jean-François Roussy1, Yacine Abed, Xavier Bouhy, Guy Boivin.   

Abstract

We report the emergence of an influenza virus A/H3N2-E119V neuraminidase variant from an elderly patient with renal dysfunction who received a suboptimal dose of oseltamivir prophylaxis. In neuraminidase inhibition assays, the E119V variant showed a 413-fold increase in the 50% inhibitory oseltamivir concentration and grew at titers comparable to those of the wild type in vitro.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24088848      PMCID： PMC3838039          DOI： 10.1128/JCM.02659-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.

Authors:  Yacine Abed; Nathalie Goyette; Guy Boivin
Journal:  Antivir Ther       Date:  2004-08

Review 2.  Neuraminidase inhibitors for influenza.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.

Authors:  Elodie Ghedin; Edward C Holmes; Jay V DePasse; Lady Tatiana Pinilla; Adam Fitch; Marie-Eve Hamelin; Jesse Papenburg; Guy Boivin
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Alicia Fry; David Shay; Larisa Gubareva; Joseph S Bresee; Timothy M Uyeki
Journal:  MMWR Recomm Rep       Date:  2011-01-21

7.  The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Authors:  Fred Y Aoki; Upton D Allen; H Grant Stiver; Gerald A Evans
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

8.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

Authors:  M Louise Herlocher; Rachel Truscon; Stephanie Elias; Hui-Ling Yen; Noel A Roberts; Suzanne E Ohmit; Arnold S Monto
Journal:  J Infect Dis       Date:  2004-09-28       Impact factor: 5.226

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.

Authors:  Yacine Abed; Andrés Pizzorno; Xavier Bouhy; Guy Boivin
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823
View more
  3 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

2.  Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches.

Authors:  N Gorišek Miksić; T Uršič; Z Simonović; L Lusa; P Lobnik Rojko; M Petrovec; F Strle
Journal:  Infection       Date:  2014-11-18       Impact factor: 3.553

3.  Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Authors:  Andrés Pizzorno; Yacine Abed; Pier-Luc Plante; Julie Carbonneau; Mariana Baz; Marie-Ève Hamelin; Jacques Corbeil; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.